TG Therapeutics Approves Key Proposals at Annual Meeting

An update from TG Therapeutics ( (TGTX) ) is now available.

On June 12, 2025, TG Therapeutics, Inc. held its Annual Meeting where stockholders representing 74.58% of the outstanding shares were present. All proposals, including the election of six directors, ratification of KPMG LLP as the independent auditor, approval of executive compensation, and amendment to the 2022 Incentive Plan, were approved, potentially impacting the company’s governance and financial strategies.

The most recent analyst rating on (TGTX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.

Spark’s Take on TGTX Stock

According to Spark, TipRanks’ AI Analyst, TGTX is a Neutral.

TG Therapeutics shows a promising recovery with strong revenue growth and improved financial metrics. The earnings call further supports this positive outlook with increased guidance and strategic advancements. However, technical indicators suggest the stock may be overbought, and the high P/E ratio indicates potential overvaluation, tempering the overall score.

To see Spark’s full report on TGTX stock, click here.

More about TG Therapeutics

TG Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of novel treatments for B-cell diseases. The company is primarily engaged in creating therapies for patients with hematologic malignancies and autoimmune diseases.

Average Trading Volume: 2,642,055

Technical Sentiment Signal: Strong Buy

Current Market Cap: $6.08B

See more insights into TGTX stock on TipRanks’ Stock Analysis page.